Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cardinal Health (NY: CAH )

71.14 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 71.14
Bid (Size) 61.10 (1)
Ask (Size) 72.78 (1)
Prev. Close 71.14
Today's Range 71.14 - 71.14
52wk Range 49.70 - 81.57
Shares Outstanding 290,441,408
Dividend Yield 2.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 Stocks Set to Soar When the Market Recovers
Daring contrarians can bid up the danger with these intriguing market ideas. 
Via InvestorPlace
Healthcare Stocks With at Least 30 Years of Dividend Increases
Among the many industry sectors to invest in, healthcare can be one of the most stable, especially regarding the dividend yield. 
Via MarketBeat

Performance

YTD
-7.29%
-7.29%
1 Month
-8.99%
-8.99%
3 Month
-10.34%
-10.34%
6 Month
+4.31%
+4.31%
1 Year
+23.51%
+23.51%

More News

Read More
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
Via TheNewswire.com
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
Via News Direct
Cardinal Health's Earnings Outlook
Via Benzinga
7 Analysts Have This to Say About Cardinal Health
Via Benzinga
Is Market Sentiment Getting Behind This Emerging Small-Cap Specialty Syringe Medical Device Company?
Via Benzinga
This Stock Could Fill Your Pockets for Years to Come
Via The Motley Fool
3 Great Value Stocks To Buy Now For Steady Long-Term Growth
Via Talk Markets
RxLive and Cardinal Health’s Outcomes collaborate to enhance connectivity between providers across transitions of care
From RxLive
Via Globe NewsWire
Is This Warren Buffett Stock a Buy for Dividend Growth Investors?
Via The Motley Fool
With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO
Via Benzinga
Battleground Stocks: 3 Heavily Shorted Meme Stocks to Watch
Via InvestorPlace
Palantir Q4 Earnings Preview: Will The Data Software Company Deliver On CEO Expectations For A 'Strong Finish To The Year'?
Via Benzinga
Why Palantir, Twilio, and HubSpot Each Surged Over 20% in January
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2023
Via Benzinga
Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?
Via Benzinga
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
Via Benzinga
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Via TheNewswire.com
Topics Economy
Exposures Supply Chain
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Via News Direct
Topics Economy
Exposures Supply Chain
Sharps Technology Is Commercializing The Future Of Specialty Syringe Systems For The Healthcare Industry Through Its Next-Gen Polymer-Based Products
Via Benzinga
Sharps Technology Is Injecting A Better Solution Into The Healthcare Syringe Industry
Via Benzinga
Buying These 2 Stocks Is a Good Way to Hedge Against a Market Crash
Via The Motley Fool
Global Drug Delivery Systems Market Size Projected to Reach $71.75 Billion By 2029
Via FinancialNewsMedia
Exposures COVID-19
2 Dividend Aristocrat Stocks To Buy And Never Sell
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.